Abstract. Pasteurella multocida toxin depresses weight gain in rats and pigs. It also affects tissues with rapidly dividing cells. In the present study, we investigated the role of this protein toxin on chondrocyte growth in vivo. Rats were divided into a single-or multiple-dose group and were given, respectively, either a single injection (0.15 or 0.6 g/kg toxin subcutaneously) or multiple injections (0.0 1-0.2 pgkg subcutaneously) of toxin. Bone (humerus) and other selected tissues were stained for bromodeoxyuridine immunoreactivity (BrDU-IR) in order to gauge cell proliferation. Physeal area was measured in rats from the multiple-dose group. Serum from singleand multiple-dose groups were tested for tumor necrosis factor a (TNF-a) and interleukin 6 (IL-6) activity using a bioassay system. Decreased weight gain, feed intake, and feed efficiency were observed in single-and multipledose groups of rats. Decreased BrDU-IR indices were present in the resting and proliferative zone chondrocytes of the humeral physis in rats from the multiple-dose group, as was decreased physeal area. Increased serum IL-6 bioactivity was present in rats after 24 hours, and no changes in TNF-a bioactivity were seen in any group.
Long bone growth prior to puberty depends on chondrocyte proliferation in the physes and the articularepiphyseal complex. Chondrocytes in the resting and proliferating zones differentiate into cells of the pre-, early, and late hypertrophic zones in a physiologically complex maturation sequence. Chondrocyte maturation is regulated by nutrients, oxygen tension, and hormones that include growth hormone, thyroid hormones, vitamin D, and parathyroid hormone. Growth factors (i.e., epidermal growth factor, basic fibroblastic growth factor, and insulin-like growth factor 16,36,40) and c y t o k i n e~~~.~~ also affect growth of physeal chondrocytes, as do cachexia and certain toxins.
Toxigenic strains of Pasteurella multocida are associated with atrophic rhinitis in growing pigs16,20 and I Disclaimer: Names are necessary to report factually on available data; however, the USDA neither guarantees nor warrants the standard of the product, and the use of the name by the USDA implies no approval of the product to the exclusion of others that may also be suitable.
can be isolated from human beings working in pig operations. I4zZ6 Decreased weight gain and small body stature often are associated with this disease and occur in pigs and rats experimentally injected with purified P. multocida t o~i n .~J~.~~.~~ Reasons for the reduced growth are difficult to determine because P. multocida toxin does not affect the feed conversion ratio (kg feed/ kg body weight gain), alter the percentage of lean meat in the carcass,I6sZ5 or reduce levels ofgrowth honnone. 17 Although the toxin does not alter these parameters, it may affect cellular proliferation in the physis and other somatic tissue (liver, testis, thymus, and small intestine) throughout the body. 38 In rats sublethal doses of toxin cause lesions in tissues with rapidly dividing cells, and in pigs toxin induces a marked reduction in bone in the ventral nasal conchae. 1-3~13~16,20,24 P. multocida toxin may act directly on cells in these tissues or indirectly via induction of cytokine release. 8 The toxin binds to the plasma membrane of two cell lines, canine osteosarcoma cells and monkey kidney (vero) cells, and induces cytotoxicity. 28 Alternatively, cytokines such as interleukin 6 (IL-6) and tumor necrosis factor (TNF) could mediate changes similar to those seen or proposed for the toxin in vivo (e.g., decreased weight gain and bone g r~w t h~~,~~) .
In this study, we use a rat model to examine the acute (I 24 hours) and intermediate (7 days) effects of a single dose of toxin and also the chronic (2 1 days) effects of multiple doses of toxin. We set out to determine whether or not the toxin (a) causes changes in cell proliferation in the physis and other tissues, namely, thymus, liver, testis, and small intestine; (b) affects the serum bioactivity of at least two cytokines known to affect bone growth, TNF-a! and IL-6; and (c) simply reduces feed intake, which, in turn, may depress cell growth. In addition, we examine the distribution of 125iodine-labeled toxin after subcutaneous injection in order to determine whether or not possible alterations in cell replication are related to the concentration of toxin in the tissues.
Materials and Methods

Animals
Two groups of rats were used to study the effects of a single high dose of toxin, and a third group of rats was used for multiple smaller doses of toxin. In the first group, rats were tested for acute (24 hours or less) toxicity in terms of cytokine response to a single dose of Pasteurella multocida toxin. Alterations in cell proliferation following a single dose of toxin were tested in the second group of rats. Chronic toxicity of multiple doses of toxin (2 1 days), in terms of both cytokine response and cell proliferation, were analyzed in the third group. In all these studies, male Holtzman rats were housed in individual cages on ground corncob bedding. Average rat weight on day 0 of each study ranged from 200 to 250 g. Rats were fed ad libitum unless specified.
Single injection of toxin and cytokine expression (24 hours)
Rats in this group ( n = 12) were given a single dose (0.6 pg/kg) of Pasteurella multocida toxin subcutaneously (0.1 ml 0.1 M phosphate-buffered saline [PBS]), and three rats each along with one control rat were killed at 2, 6, and 24 hours posttoxin. Sera were collected from these rats, stored at -60 C, and assayed for cytokine (TNF-a, IL-6) expression. Blood for differential counts and tissues for histopathology were not taken from these rats because numerous, previous similar studies have lacked change^.^,^^,^^ Therefore, the I-day group of rats was used for cell proliferation studies.
Single injection of toxin and cell proliferations (7 days)
In this group of rats ( n = 24), 12 were given a single subcutaneous injection of 0.1 ml toxin (0.15 pg/kg), and 12 were control rats (injected with 0.1 mlO.1 M PBS). The rats were weighed daily, as was the weight of rat chow consumed by each rat. At the end of 7 days, rats were given a single intraperitoneal injection of 40 pg bromodeoxyuridine (BrDU; in 0.1 M PBS) and then, 2 hours later, anesthetized with CO,, killed by CO, overdose, and necropsied. Blood was collected in ethylenediaminetetraacetate (EDTA) for total and differential counts; cytokine levels were not determined for this group. Tissues, including liver, testis, thymus, proximal humerus, spleen, kidney, duodenum, pancreas, cecum, and colon, were placed in tissue cassettes and fixed for 8 hours (or less) in zinc-formalin. Bone (humerus) was decalcified for <24 hours in EDTA-HCI (Baxter Scientific Products, McGraw Park, IL). Tissues were then routinely processed, embedded in paraffin, and sectioned. All of these tissues were examined for histologic lesions, and humeral growth plate, liver, thymus, testis, and duodenum were assayed for bromodeoxyuridine immunoreactivity (BrDU-IR).
Multiple doses of toxin (21 days)
A third group of rats ( n = 24) was divided into six treatment groups ( n = 4/group). Each group received treatments for 2 1 days of alternate-day injections of either (1) 0.1 ml 0.2 M PBS, (2) 0.025 pg/kg toxin, (3) 0.05 pg/kg toxin, (4) 0.10 pg/ kg toxin, (5) 0.20 pg/kg toxin, or (6) no injections but fed 80% of the diet of control rats. Rat weight and the weight of consumed rat chow were recorded. Restricted diets were calculated as 80% of the average weight of feed consumed by control rats during the preceding week. The restricted diet group was included to determine whether or not food restriction altered cell proliferation as compared to toxin-treated rats with decreased feed intake and reduced weight gain. The entire study was repeated with a second set of rats ( n = 20). Thus, a total of 40 rats was used in the chronic toxicity study.
At 21 days, the rats were anesthetized (CO,), injected intraperitoneally with BrDU, and then, 2 hours later, bled by cardiac puncture, killed by CO, overdose, and necropsied. Blood for cell counts, sera for cytokine analysis, and tissues for BrDU-IR were collected as already described.
Toxin preparation
P. multocida toxin was purified according to previously described protocol~.~.~~ Briefly, nonencapsulated strain P-4533 was grown on horse blood agar, lysed, and centrifuged, and crude toxin was precipitated with ammonium sulfate. The precipitate was resuspended in 1 ml phenylmethylsulfonyl fluoride and centrifuged, and the supernatant was applied to a 2.6-x -19-cm diethylaminoethanol-sepharose (Pharmacia Five Chemicals, Piscataway, NJ) column, and fractions were collected. The appropriate peak was applied to a 4.4-x -85-cm Sephacryl S-200 (Pharmacia) column, and toxin was concentrated and twice passed over a polymyxin column. This procedure produced toxin that was free of detectable levels of lipopolysaccharide (LPS) using immunoabsorbent assays. The toxin was aliquoted, stored at -70 C, and thawed once. The thawed toxin was kept cold on crushed ice and injected into animal subjects within 1 hour of thawing.
Determination of cell proliferation
Histologic sections of target organs were stained with a immunocytochemical procedure to detect cells undergoing DNA synthesis as determined by BrDU-IR. BrDU-IR is a A minimum of 300 cells from the resting and proliferating zones of the physis were counted, as were 300 round cells (lymphocytes and lymphoblasts) from cortex and medulla of the thymus and a minimum of 300 hepatocytes. After capturing an image of the tissue, the operator interactively selected the area to be measured by drawing around the edge of the imaged sample, excluding any cells not fully in the image screen. Appropriate cell types in each area were then calculated by marking each brown-stained (immunoreactive for BrDU) cell followed by an automated count and then marking each blue-stained (nonimmunoreactive) cell followed by an automated count. Software recorded each cell that was marked so that no cell was counted more than once.
Total area of the region (data not included here) plus the counts of brown and blue cells was measured and recorded for each sample. Sections of duodenum were counted by visual inspection with a light microscope because labeling was extremely intense. A total of at least five crypts with more than 150 cells from each section of duodenum was measured. Only crypt cells subjacent to the base of the intestinal villi were counted. In these areas, goblet cells were not present, and granulated cells (Paneth cells) were not counted. Labeling indices between treatment groups were compared using analysis of variance (ANOVA). Physeal areas were measured by outlining the top and bottom margins of the physis (Fig. 1) . The sides of the physis were demarcated by a line extending from the internal epiphysal cortex to the internal diaphyseal cortex. Physeal areas were measured in rats from the chronic group because this was the only group with decreased chondrocyte BrDU-IR.
Cytokine bioassays
The activity levels of the cytokines IL-6 and TNF-a were determined in serum samples collected at the terminal bleedings. These measurements were made by using in vitro cell bioassays with cell lines uniquely sensitive to particular cytokines. Assays were conducted per described methods with the following slight m~d i f i c a t i o n s .~~~~ Serum collected from rats was stored at -60 C until thawed for cytokine bioassays for IL-6 and TNF-a. The IL-6 bioassay was conducted using 7TD 1 .B3 cells, an IL-6-dependent cell line (murine plasmacytoma, American Type Culture Collection). Samples and standards (human recombinant IL-6, Genzyme Corporation, Cambridge, MA) were serially diluted in 96-well microtiter plates and pulsed with [3H]thymidine for 18 hours, harvested, and counted. Activity in samples was determined via linear regression analysis between concentration and incorporated radioactivity.
Serum for TNF-a activity was analyzed using WEHI 164 cells, a TNF-cytotoxic cell line (murine fibrosarcoma, American Type Culture Collection). Samples and standards (human recombinant TNF-a, Genzyme Corporation) were serially diluted in 96-well microtiter plates, 3 x lo4 WEHI cells were added to each well, and plates were incubated at 37 C in 5% CO, for 20 hours. Dimethylthiazol diphenyltetrazolium bromide (MTT) dye was added to each well, and plates were again incubated for 4 hours. Acidified propanol was added to each well to solubilize formazan crystal formed by interaction of the MTT and active cells. Plates were incubated at room temperature in a humidity chamber, and absorbance in each well was measured on an ELISA reader (ODs60-OD690). TNF activity is inversely related to absorbance and is calculated by comparison with values obtained for standards. Differences between treatment groups were determined using ANOVA.
Distribution of injected 1251-labeled toxin
Purified toxin was iodinated using 1,3,4,6-tetrachloro-3a,6-a-diphenylglycouril (iodogen).20 Toxin (50A pg) in 50 pl of 4.0 M Tris, 4.0 mM EDTA buffer (pH 7.4), and 1 mCi of l z s I (as NaI) were added to an iodogencoated microfuge tube and shaken gently for 1 minute. The reaction was terminated by transferring the mixture to a clean tube. Iodinated toxin was separated from free iodide using gel filtration chromatography on a PD-10 minicolumn (Pharmacia Fine Chemicals) preequilibrated with 0.01 M Tris, 0.01 M NaCl, 4.0 mM EDTA elution buffer (pH 7.8). Fractions (0.5 ml) were eluted and 10-p1 aliquots of each fraction counted in a gamma counter (Beckman Instruments, Inc., Palo Alto, CA) to determine the peak of the radio-iodinated toxin. Fractions containing radio-labeled toxin were pooled and stored at 4 C. The specific activity of iodinated toxin, determined using dot blot assays, was 0.3 pCi/0.002 pg.
Iodinated toxin was solubilized, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophore~is,~ transferred to nitro~ellulose,~ and detected by autoradiography (Fig. 2) . Development of the autoradiograph revealed one band of MW 145,000 daltons. Biological activity of iodinated toxin was confirmed in mouse lethality experiments. In these, 0.8 pg of iodinated toxin and noniodinated toxin was injected subcutaneously into three mice each. All mice died by 96 hours.
IIz5toxin experimental design. Subcutaneously, another set of rats (n = 16) received subcutaneous injections of 3 p g l kg unlabeled or radio-labeled toxin in 0.5 M Tris, 0.002 M EDTA buffer (pH 8.3) to determine the tissue tropism of toxin injected. Two rats from each group were necropsied at 2,4,8, and 24 hours postinjection. At 24 hours, rats receiving labeled or unlabeled toxin exhibited ruffled fur and hunched posture, symptoms characteristic of this toxin in mice and rats. To avoid cross-contamination, nonradioactive rats were necropsied first, new plastic-lined drop towels were placed on the necropsy table between each rat, rinsed nonradioactive instruments were used for each organ, instruments were thoroughly washed between rats and checked for radioactivity, each organ was placed in disposable plastic tubes, and workIodination of toxin. ers changed gloves between rats. The table, instruments, gloved hands, and workspace were continually monitored for contamination using a hand-held Eberline Model 120E gamma counter with a GM-SK-1 probe (Eberline Instrument Corporation, Santa Fe, NM). Tissues counted for radioactivity included the following: skin and subcutaneous tissue at the injection site, thymus, lung, heart, liver, kidney, testis, stomach, proximal femur, tail, proximal humerus, spleen, small intestine, pancreas, adrenal gland, brain, eye, thyroid, bladder, and salivary gland. Skin and subcutaneous tissue were removed from tail tissue, and ingesta or fecal contents were removed from stomachs and intestines. Preweighed tissue sections were counted in a Beckman LSC 6000 gamma counter (Beckman Instruments, Inc.). Counts were calculated on a per gram basis.
Results
Clinical signdweight gain
Rats had ruffled pelage, were reluctant to move, and had a hunched posture 3-5 days after toxin exposure. In addition to these behavioral changes, ulcerations and scab formation with alopecia were present at injection sites of rats given multiple injections (2 1 days).
Weight gain decreased in toxin-treated rats (average = 19 g) compared to controls (average = 58 g) in the single-injection (7 days) group. Feed efficiency, calculated as the amount of weight gained (grams) per gram of feed consumed, also decreased (average toxin treated = 0.12; average control = 0.31). Toxin treatment was associated with decreased weight gain, feed consumption, and feed efficiency in the multiple-dose (2 1 days) group (Table 1) . Rats given the highest dose of toxin (0.2 &kg) had the least weight gain, lowest amount of feed consumption, and smallest feed efficiency score. The weight gain (24 g) in these rats was less than that fed to rats in the restricted diet group (96 g) and much less than the control rats (1 77 g). Rats given a restricted diet consumed 80% (by design) of what control rats ate, whereas rats given 0.025, 0.05, 0.1, and 0.2 pg/kg ate 95,93,82, and 69%, respectively, of what was consumed by control rats (Table 1) . Thus, consumption by 0.1 and 0.2 toxin groups was similar to the 80% diet fed to the restricted group. Weight parameters were not measured for acute toxicity rats because previous studies have demonstrated no effects of toxin on weight gain in <24 hours.
Cell proliferation
Labeling indices of physeal chondrocytes were significantly decreased in rats of the multiple-dose (21 days) group given the highest doses of toxin (4.3 k 2.3 at 0.2 pg) and markedly decreased (6.1 * 2.1 for 0.1 pg) when compared to control (10.3 k 2.3) and restricted (1 1.2 * 3.1) diet rats (Table 2 ). BrDU-IR was seen within the cells of the distal resting zone area and proliferating zone; cells of the hypertrophy zone were not stained with BrDU-IR (Fig. 2) . Significant decreases in total area of the physeal plate were also present Increased BrDU-IR was present in hepatocytes (Table 2) in periportal areas of rats given the 0.1 and 0.2 p g toxin in the multiple-dose (21 days) group. In addition to the increased BrDU-IR in these rats, multifocal hepatocytes were in various stages of mitotic division. Hepatocytes in affected areas often had features of degeneration characterized by rounded cell borders, moderately vacuolated cytoplasm, and increased nuclear basophilia. A consistent finding in these areas was necrosis of low numbers of individual hepatocytes. No significant differences were present between control rats and rats given the lowest two doses of toxin or in rats fed a restricted diet. Hepatic labeling indices were not significantly different between toxin and control rats in the single-dose (7 days) group.
BrDU-IR in testis was greatly reduced in rats given multiple doses of toxin. This reduction was associated with marked diffuse testicular degeneration and necrosis of spermatogonial cells and spermatids as previously described.' These lesions prohibited BrDU-IR analysis and were present in those rats receiving multiple doses of 0. l and 0.2 pg/kg. Lesions and reduced BrDU-IR were not seen in other groups. No significant differences in toxin-treated rats were present in labeling indices for thymic cortex and medulla and duodenum in both single-and multiple-dose groups when compared to controls.
Cytokine response
There were significant (P < 0.0 1 ) elevations in serum IL-6 bioactivity of toxin-treated rats (39.69 k 6.43 in toxin-treated versus 7.78 k 0.21 in controls) at 24 hours posttoxin. Elevations were not present in rats killed at 2 and 6 hours. Significant elevations of were present in rats in the multiple-dose (21 days) group as well (Table 2) .
Distribution of iodinated toxin
Different organs vaned greatly in amount of accumulated radio-label, and there were no obvious trends among animals necropsied at the various times. Levels of radioactivity in all tissues collected from 1251-toxininjected rats exceeded those found in homologous control rat tissues, and highest counts were present in injection-site subcutaneous tissue. Counts per gram for sums of all necropsy times were adjusted for background counts recorded in order of decreasing frequency (Table 3 ) using the following formula: C = Log,, (site count/background count).
The highest amounts of radioactivity in decreasing order were liver > stomach > heart > bone (femur) > lung > tail > testis > bone(humerus) > other organs > brain.
Discussion
The decreased BrDU-IR in physeal chondrocytes at the 0.2-pg level, in conjunction with the general trend of reduced BrDU-IR at other doses and decreased phy- It is also possible that the toxin directly binds chondrocyte receptors and inhibits growth and proliferation. The toxin causes lesions in tissues with rapidly dividing cells in vivo (testis, liver).3 In vitro, the toxin binds canine osteosarcoma and vero cell plasma membranesz8 and increases mitogenic activity in 3T3 and Rat-1 fibr~blasts.~J~,~* The toxin is internalized into small caveolae and activates inositol-phospholipid breakdown, which leads to phosphorylation of 80-kd substrate of protein k i n a~e .~~,~~ It is a potent mitogen and stimulator of anchorage-independent growth with greater effects than either epidermal growth factor or platelet-derived growth factor. l 8 Thus, decreased chondrocyte proliferations in this study differ from other fibroblast studies in vitro and reflects the complexity of functional activity when in vivo.
It is unlikely that decreased feed intake in toxintreated rats was the sole reason for decreased physeal chondrocyte BrDU-IR, because rats fed the 80% diet had no BrDU-IR alterations. However, this is complicated by several factors. First, decreased feed efficiency (increased amounts of feed to produce weight gain) in toxin-treated rats suggests that changes may have occurred in either digestion or absorption of ingested feed. The anatomical integrity at the light microscopic level of the intestinal mucosa remained intact, and BrDU-IR index changes were not seen. However, cell metabolic perturbations and alterations in glycocalyx enzymes, electrolyte transport, and mucosal immunity cannot be ruled out. Second, stress-induced metabolic alterations in peripheral tissues, such as muscle and digestive tissues (pancreas and liver), could occur secondary to a variety of factors (e.g., the toxin, cortisol, cytokines). Finally, the decreased food intake and impaired weight gain in toxin-treated rats could also be due to toxin-or cytokine-induced changes in hypothalamic nuclei that regulate feed intake. Very little iodinated toxin was present in the brain; however, it may localize in specific areas of the brain, such as the periventricular organs, which are not protected by the blood-brain barrier and could be activated by the toxin, IL-6, or both.34 Several cytokines are present in the neurons of the central nervous system, and levels of Fos (indicating neuronal activation) and the messenger RNAs of IL-1 and IL-6 are increased in neurons within and associated with the periventricular organs of LPS-treated rats.15 Although toxin or cytokine activation of the hypothalamus may later feed intake, it cannot be determined from this study whether or not this would alter chondrocyte proliferation through the release of certain pituitary hormones (growth hormone, thyroxine). One of these, growth hormone, is not altered significantly in toxin-treated pigs. 17 Increased BrDU-IR in liver may be a regenerative attempt by hepatocytes to replace damaged cells. The toxin, which is spread hematogenously according to the radio-labeling studies, is a known hepatoto~in,~.~ and hepatocellular degeneration was present in the highdose rats of the multiple-dose (2 1 days) group. It could also be that the toxin is simply mitogenic to hepatocytes, as the toxin is mitogenic to cells in vit1-0.~~ Loss of functional hepatic parenchyma may have contributed to the elevated IL-6 in the serum because hepatocytes express receptors for this cytokine.21 This may account for elevations of IL-6 and the lack of TNF response. Other metabolic functions (e.g., bile acid uptake, enzyme function) of the liver are similarly alt e~e d ,~.~ and these may also affect chondrocyte proliferation.
Decreased BrDU-IR in testis was not surprising because ultrastructural studies have demonstrated spermatogonial cell damage in toxin-treated rats.3 Similar to brain, seminiferous tubules ofthe testis are protected by the blood-testis barrier. The tubule damage may occur secondary to activation of testicular interstitial macrophages by either toxin or IL-6.
Although BrDU-IR alterations were not seen in small intestine and thymus, other features of toxicity (decreased weight gain, hematologic changes, clinical debilitation, and skin ulcerations) were consistently present in the single-(7 days) and multiple-dose (21 days) g r o u~s .~~,~~ Alterations in BrDU-IR in these organs may only be seen at near cytotoxic levels. Absence of BrDU-IR alterations in single-dose rats may be because prolonged exposure to toxin is necessary to cause direct effects on cells or increases in IL-6.
Distribution of the radio-labeled toxin was widespread and appears to be associated with hematogenous spread. The high level of iodinated toxin in hepatic tissue was not surprising because this organ receives a large blood flow and hepatocellular damage is often seen in toxin-treated rats and pig^.^,^,^ Interestingly, relatively high levels were also present in bone and testis, tissues with altered BrDU-IR. This 
